# Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

> **NCT06858410** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 36 (estimated)

## Conditions studied

- Neoadjuvant Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** lorlatinib
- **OTHER:** concurrent/sequential platinum-based chemoradiotherapy

## Key facts

- **NCT ID:** NCT06858410
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2030-03
- **Final completion:** 2030-08
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06858410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06858410, "Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06858410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*